These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 27310969

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J, Ji DN, Shen Y, Guan JL, Zheng SB.
    Ann Clin Lab Sci; 2017 Mar; 47(2):171-177. PubMed ID: 28442519
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ.
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [Abstract] [Full Text] [Related]

  • 5. Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance.
    Hibi T, Hirohata S, Hisamatsu T, Kikuchi H, Takeno M, Sato N, Mizuno N, Tashiro M, Susuta Y, Ishigatsubo Y.
    Adv Ther; 2024 Dec; 41(12):4476-4497. PubMed ID: 39412631
    [Abstract] [Full Text] [Related]

  • 6. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y, Takeuchi M, Ishihara M, Shibuya E, Yamane T, Hasumi Y, Kawano S, Kimura I, Mizuki N.
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, Ye BD, Song GA, Lee Y, Kim Y, Lee Y, Kim WH, BEGIN Study Group.
    Gut Liver; 2023 Sep 15; 17(5):777-785. PubMed ID: 36578194
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
    Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, Kim HJ, Kim EY, Kim KO, Jang BI, Kim WH.
    Inflamm Bowel Dis; 2013 Aug 15; 19(9):1833-8. PubMed ID: 23702810
    [Abstract] [Full Text] [Related]

  • 9. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb 15; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 10. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA, Erden A, Kilic L, Peynircioğlu B, Karadag O, Kalyoncu U.
    Acta Clin Belg; 2019 Oct 15; 74(5):364-369. PubMed ID: 30220250
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y.
    BMC Gastroenterol; 2015 Aug 14; 15():103. PubMed ID: 26271624
    [Abstract] [Full Text] [Related]

  • 13. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, Hernández-Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Maíz O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Valle DD, Aurrecoechea E, Caracuel MA, García-González AJ, Álvarez ER, Vegas-Revenga N, Demetrio-Pablo R, Castañeda S, González-Gay MA, Hernández JL, Blanco R, Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease.
    J Rheumatol; 2021 May 14; 48(5):741-750. PubMed ID: 33004539
    [Abstract] [Full Text] [Related]

  • 14. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.
    BMC Pediatr; 2019 Oct 13; 19(1):351. PubMed ID: 31607268
    [Abstract] [Full Text] [Related]

  • 15. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY, Kang B, Choe YH.
    Gut Liver; 2019 Sep 15; 13(5):541-548. PubMed ID: 30970435
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
    Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T.
    Inflamm Bowel Dis; 2008 Sep 15; 14(9):1259-64. PubMed ID: 18393375
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.
    PLoS One; 2018 Sep 15; 13(8):e0201956. PubMed ID: 30114224
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.